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CT numbers, thus demonstrating the need for CBCT 
corrections as investigated in this work. The DIR inaccurately 
matches the outline of the bladder (see dashed circle), 
leading to a wrong anatomy in the vCT. In contrast, the 
CBCTcor bladder anatomy agrees well with the original CBCT.  
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Its excellent soft tissue contrast makes MRI extremely well 
suited for guidance of external beam radiotherapy.  
In recent years, using cone beam CT-linac radiotherapy 
systems, great success has been realized in the minimal 
invasive treatment of prostate tumours, stereotactic ablative 
body radiotherapy of lung tumours and stereotactic 
treatment of tumours of the brain. For these tumours, there 
is good visualization of the tumour itself or there is a good 
visualization of tumour related structures or fiducial markers. 
There is a clear trend towards better targeting with less 
normal tissue involvement and thus less toxicity, less surgery 
and less fractionation. However, for most other tumour 
locations the limited visualization using cone beam CT and 
the lack of dynamic information hinders this development. 
On-line and real-time MRI guidance may offer the possibility 
to implemented this stereotactic revolution for most 
remaining tumour locations like radiotherapy of tumours of 
the rectum, oesophagus, pancreas, kidney, individual lymph 
nodes, etc. This may provide a breakthrough in the 
application of radiotherapy and redefine the relation 
radiotherapy and surgery.  
Essential is the availability of high quality MRI (e.g.1.5T 
Philips Ingenia) during the actual treatment process. The 
design of the experimental UMCUtrecht/Elekta MRI-Linac 
combination has been described in Lagendijk et al. [2008] 
and Raaymakers et al. (2009). The MRI accelerator facilitates 
good soft tissue visualization and continuous patient anatomy 
updates regarding translations, rotations and deformations of 
targets and organs at risk. Accounting for this, demands high 
speed, online intensity-modulated radiotherapy re-
optimization. The MRI must supply real-time information 
about the actual position of the tumour and organs at risk 
and the on-line treatment planning must be able to deal with 
this. Dedicated sequences and correction protocols are being 
developed to guarantee extreme fast and geometrically 
correct MR imaging. Essential is that the complete 3D 
anatomy can be followed in real-time. Treatment planning 
procedures are being developed which can optimize the dose 
delivered on the actual anatomy. 
The radiation dose is being delivered with the patient in a 
1.5T magnetic field. The actual dose deposition, beam 
characteristics and absolute dosimetry must be evaluated for 
this magnetic field environment. 
The clinical introduction of the MRL system is being 
organized within an international consortium. Within this 
consortium structure imaging protocols are being optimizes, 
‘blue sky’ approached are being discussed for several tumour 
groups and the actual clinical trials are being designed. 
 
Keywords:  
MRI, on-line, adaptive 
 
References: 
Lagendijk JJW et al. Radiother Oncol. 2008; 86(1), 25-9  
Raaymakers BW et al. Phys Med Biol. 2009; 54(12), N229-37  
 
132 
Current status of particle therapy in the Netherlands 
J.A. Langendijk 
 
In 2009, the Health Council of Ministry of Health published 
the Horizon Scanning Report Proton Radiotherapy, which 
paved the way for the clinical introduction of proton therapy 
in the Netherlands. In this report, four categories of 
indications were identified, including: standard indications 
(e.g. pediatric patients), prevention of secondary tumors in 
young patients with favorable prognosis (e.g. Hodgkin 
lymphoma), potential indications (i.e. dose escalation 
without enhancing toxicity) and the model-based indications 
(i.e. prevention of side effects). The model-based indications 
are the largest group of indications. In this category, patients 
will only be selected for proton therapy after an individual 
planning comparison and if the difference in dose translates 
in a minimal difference in NTCP (ΔNTCP). This model-based 
approach has been recognized by the Health Insurance Board 
as well, which means that patients selected for proton 
therapy according to this approach will receive 
reimbursement for their treatment. 
In addition to this, the Ministry of Health, together with the 
proton therapy initiatives launched a national plan for proton 
therapy, which includes the realization of four small to 
medium sized proton therapy centers, with a geographic 
distribution over the country that foresees optimal 
accessibility of proton therapy for all eligible patients in the 
Netherlands. The maximum capacity to be created is 2,200 
patients per year, divided among these four centers. These 
centers are now under construction. 
Consensus has been reached on a national level regarding the 
threshold for ΔNTCP to be selected for proton therapy. More 
detailed indication protocols are now developed coordinated 
by the National Proton Therapy Platform, in which all 
radiotherapy departments are represented.  
In addition, the four initiatives closely collaborate to create 
a national prospective data registry program to create a 
rapid learning health care system which can be used to 
develop and externally validate NTCP-models and to validate 
the added value of proton therapy to reduce radiation-
induced side effects. 
In this way, the Netherlands is one of the first countries 
worldwide that will realize a well balanced national plan for 
proton therapy in which this new technology will be 
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Purpose: In 2005, the word “theranostics” was used for the 
first time for describing the use of imaging for therapy 
planning in radiation oncology. It is defined as the use of 
individual patient-level biological information in choosing the 
optimal therapy for that individual [1]. In Nuclear Medicine 
this term describes the use of short-lived tracers for 
predicting the absorbed doses in molecular radiotherapy and, 
thus, safety and efficacy of a treatment. 
Materials/Methods: For pre-therapeutic dosimetry for the 
purpose of dose-planning or for post-therapeutic dose 
verification, quantitative imaging of the biokinetics of the 
administered radiolabelled substance is necessary followed 
by the calculation of the absorbed doses with potential 
inclusion of biological effects. This comprises the following 
three steps: 
a) Quantitative Imaging 
The established method for quantitative imaging for 
dosimetry relies on the measurement of the biokinetics 
by serial PET/CT, SPECT/CT or whole body scan. For 
